Epidemiology, costs, and the economic burden of fibromyalgia
Rheumatologische Schwerpunktpraxis, Bahnhofstraße 95, 82166 Graefelfing, Munich, Germany
Arthritis Research & Therapy 2009, 11:117 doi:10.1186/ar2715
See related research by Sicras-Mainar et al., http://arthritis-research.com/content/11/2/R54Published: 30 June 2009
The assumption that fibromyalgia is associated with a major impact on the utilization of both healthcare and nonhealthcare resources has not been thoroughly supported by evidence-based data. Despite the differences between healthcare and sociopolitical systems in various countries, more recent results from epidemiological research now clearly demonstrate the socioeconomic burden of fibromyalgia and its comorbidities. The costs of the disease, calculated in single studies and countries, allow estimates for populations in other countries. The alarming results highlight the urgent need both for more research (including pathophysiology and epidemiology) and for the acceptance of emerging treatment challenges.